# Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus

> **NCT02250222** · PHASE1 · COMPLETED · sponsor: **Ligand Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** LGD-6972
- **DRUG:** Placebo (Captisol ®)

## Key facts

- **NCT ID:** NCT02250222
- **Lead sponsor:** Ligand Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-05
- **Final completion:** 2015-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2015-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02250222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02250222, "Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02250222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*